ArticlePLoS neglected tropical diseases2016
Antibody-Mediated Neutralization of the Exotoxin Mycolactone, the Main Virulence Factor Produced by Mycobacterium ulcerans.
Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Buruli ulcer.Nature reviews. Disease primers · 2025Review
- Review
- Unlocking Opportunities forACS infectious diseases · 2024Review
- Multi-epitope vaccine candidates based on mycobacterial membrane protein large (MmpL) proteins againstOpen biology · 2023Article
- CD1 and iNKT cells mediate immune responses against the GBS hemolytic lipid toxin induced by a non-toxic analog.PLoS pathogens · 2023Article
- Can membrane composition traffic toxins? Mycolactone and preferential membrane interactions.Biophysical journal · 2022Article
- Genome-wide screening identified SEC61A1 as an essential factor for mycolactone-dependent apoptosis in human premonocytic THP-1 cells.PLoS neglected tropical diseases · 2022Article
- Density Functional Theory-Based Studies Predict Carbon Nanotubes as Effective Mycolactone Inhibitors.Molecules (Basel, Switzerland) · 2022Article
- Identification of potential candidate vaccines againstFrontiers in immunology · 2022Article
- Overview: Mycolactone , the Macrolide Toxin of Mycobacterium ulcerans.Methods in molecular biology (Clifton, N.J.) · 2022Article
- An Antigen Capture Assay for the Detection of Mycolactone, the Polyketide Toxin ofJournal of immunology (Baltimore, Md. : 1950) · 2021Article
- Development of an ELISA for the quantification of mycolactone, the cytotoxic macrolide toxin of Mycobacterium ulcerans.PLoS neglected tropical diseases · 2020Article
- The immunology of other mycobacteria: M. ulcerans, M. leprae.Seminars in immunopathology · 2020Review
- Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.Infection and immunity · 2020Article
- Article
- Buruli ulcer: The Efficacy of Innate Immune Defense May Be a Key Determinant for the Outcome of Infection WithFrontiers in microbiology · 2020Review
- Mycolactone Toxin Membrane Permeation: Atomistic versus Coarse-Grained MARTINI Simulations.Biophysical journal · 2019Article
- Molecular Informatics Studies of the Iron-Dependent Regulator (ideR) Reveal Potential Novel Anti-Molecules (Basel, Switzerland) · 2019Article
- Recombinant Antibodies against Mycolactone.Toxins · 2019Article
- Membrane perturbing properties of toxin mycolactone from Mycobacterium ulcerans.PLoS computational biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycolactone, the macrolide exotoxin produced by Mycobacterium ulcerans, causes extensive tissue destruction by inducing apoptosis of host cells. In this study, we aimed at the production of antibodies that could neutralize the cytotoxic activities of mycolactone. METHODOLOGY/PRINCIPAL
findingsUsing the B cell hybridoma technology, we generated a series of monoclonal antibodies with specificity for mycolactone from spleen cells of mice immunized with the protein conjugate of a truncated synthetic mycolactone derivative. L929 fibroblasts were used as a model system to investigate whether these antibodies can inhibit the biological effects of mycolactone. By measuring the metabolic activity of the fibroblasts, we found that anti-mycolactone mAbs can completely neutralize the cytotoxic activity of mycolactone. CONCLUSIONS/SIGNIFICANCE: The toxin neutralizing capacity of anti-mycolactone mAbs supports the concept of evaluating the macrolide toxin as vaccine target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.